The WHO Deputy Director General for Access to Medicines, Mariangela Simao, reported that, after stopping the evaluation by legal procedures, the international organization and the Russian government are once again advancing in the “emergency” approval of the drug developed by the Gamaleya National Research Center for Epidemiology and Microbiology.
“I am pleased to report that in the discussions we have with the Russian Government, this problem has yet to be resolved and as soon as these processes are finished we will be in a position to resume the procedure,” Simao said at a press conference, according to The Moscow media. Time.
“I am happy to tell you that negotiations with the Russian government on this issue are about to be resolved,” she announced.
“You still need to provide us with some information and questions about the completion of the inspections at the various production sites in Russia are still pending, but I am pleased to tell you that the process is about to start,” he added.
The announcement comes almost a week after Russian Health Minister Mikhail Murashko stated at the end of a meeting with WHO chief Tedros Adhanom Gebreyesus that “all barriers have been removed” to the recognition of the immunizing Sputnik. V.
Secondly, Russia indicated that it will locate 50% of the production of this vaccine for next month in foreign facilities.
“By November, more than 50 percent of Sputnik V and Sputnik Light will be produced outside of Russia,” said the director of the Russian Direct Investment Fund (RDIF), Kiril Dmitriev, at the Bloomberg Invest Global conference, quoted by the agency of Sputnik news.
To date, the WHO has included in the list of drugs approved for emergency use those of Moderna, Pfizer / BioNTech, Johnson & Johnson and the two versions of AstraZeneca, the one made in India (called Covishield) and the one developed in Korea. from the south.
It also granted that authorization to those of Chinese origin from Sinovac (called CoronaVac) and Sinopharm.
Sputnik was widely administered in Russia, where the relevant entities approved its use, as well as in several Latin American countries.
Sputnik Light, which is the first component of Sputnik V, has an efficiency of between 78% and 83%, according to data from the Ministry of Health of the province of Buenos Aires.
David William is a talented author who has made a name for himself in the world of writing. He is a professional author who writes on a wide range of topics, from general interest to opinion news. David is currently working as a writer at 24 hours worlds where he brings his unique perspective and in-depth research to his articles, making them both informative and engaging.
